|
prostaglandin receptor antagonist
|
CHEBI_138887 |
|
|
EC 1.3.99.* (oxidoreductase acting on donor CH-CH group, with other acceptors) inhibitor
|
CHEBI_76859 |
|
|
EC 2.5.1.48 (cystathionine gamma-synthase) inhibitor
|
CHEBI_137566 |
|
|
inclusion conjunctivitis
|
DOID_13800 |
|
|
conjunctival disease
|
DOID_4251 |
|
|
familial combined hyperlipidemia
|
DOID_13809 |
|
|
EC 1.9.3.1 (cytochrome c oxidase) inhibitor
|
CHEBI_38500 |
|
|
EC 1.9.3.* (oxidoreductase acting on donor heme group, oxygen as acceptor) inhibitor
|
CHEBI_76870 |
|
|
SNB75 cell
|
CLO_0009905 |
|
|
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor
|
CHEBI_74213 |
|
|
viral entry into host cell
|
GO_0046718 |
|
|
complement component 3 deficiency
|
DOID_8354 |
|
|
complement deficiency
|
DOID_626 |
|
|
lymphogranuloma venereum
|
DOID_13819 |
|
|
granuloma inguinale
|
DOID_9113 |
|
|
yellow fever
|
DOID_9682 |
|
|
EC 2.2.1.* (transketolase/transaldolase) inhibitor
|
CHEBI_76876 |
|
|
emetic
|
CHEBI_149552 |
|
|
anticoronaviral agent
|
CHEBI_149553 |
|
|
EC 2.4.99.* (glycosyltransferases transferring other glycosyl groups) inhibitor
|
CHEBI_76882 |
|
